Bank of New York Mellon Corp Has $1.65 Million Holdings in Assembly Biosciences Inc (ASMB)
Bank of New York Mellon Corp raised its position in Assembly Biosciences Inc (NASDAQ:ASMB) by 10.1% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 47,317 shares of the biopharmaceutical company’s stock after buying an additional 4,330 shares during the quarter. Bank of New York Mellon Corp’s holdings in Assembly Biosciences were worth $1,653,000 at the end of the most recent reporting period.
Other large investors have also recently made changes to their positions in the company. Nationwide Fund Advisors bought a new position in Assembly Biosciences in the 2nd quarter valued at $161,000. Parametric Portfolio Associates LLC boosted its holdings in Assembly Biosciences by 13.6% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 10,078 shares of the biopharmaceutical company’s stock valued at $208,000 after purchasing an additional 1,203 shares during the period. Legal & General Group Plc bought a new position in Assembly Biosciences in the 2nd quarter valued at $212,000. Wells Fargo & Company MN bought a new position in Assembly Biosciences in the 2nd quarter valued at $213,000. Finally, State of Wisconsin Investment Board bought a new position in Assembly Biosciences in the 2nd quarter valued at $227,000. 61.41% of the stock is owned by hedge funds and other institutional investors.
In other news, Director William R. Ringo sold 1,000 shares of Assembly Biosciences stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $29.55, for a total transaction of $29,550.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold a total of 4,000 shares of company stock valued at $157,660 over the last ninety days. 19.60% of the stock is currently owned by insiders.
Shares of Assembly Biosciences Inc (ASMB) opened at $41.73 on Wednesday. Assembly Biosciences Inc has a fifty-two week low of $12.50 and a fifty-two week high of $52.37. The stock has a market cap of $726.01, a price-to-earnings ratio of -14.05 and a beta of 0.90.
Several research analysts have commented on ASMB shares. Zacks Investment Research raised shares of Assembly Biosciences from a “hold” rating to a “buy” rating and set a $37.00 price target for the company in a report on Wednesday, November 15th. Jefferies Group started coverage on shares of Assembly Biosciences in a report on Wednesday, November 8th. They issued a “buy” rating and a $50.00 price target for the company. BidaskClub downgraded shares of Assembly Biosciences from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 6th. Chardan Capital reissued a “buy” rating on shares of Assembly Biosciences in a report on Sunday, September 17th. Finally, B. Riley started coverage on shares of Assembly Biosciences in a report on Friday, January 5th. They issued a “neutral” rating and a $35.00 price target for the company. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $39.25.
TRADEMARK VIOLATION NOTICE: “Bank of New York Mellon Corp Has $1.65 Million Holdings in Assembly Biosciences Inc (ASMB)” was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another site, it was illegally stolen and reposted in violation of international copyright and trademark law. The legal version of this piece can be viewed at https://www.watchlistnews.com/bank-of-new-york-mellon-corp-has-1-65-million-holdings-in-assembly-biosciences-inc-asmb/1800942.html.
Assembly Biosciences Profile
Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.
Want to see what other hedge funds are holding ASMB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Assembly Biosciences Inc (NASDAQ:ASMB).
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.